Real-world cost of disease-modifying treatments administered by intravenous infusion in relapsing-remitting multiple sclerosis patients from Argentina
- 1 April 2026
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 110, 107173
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in ArgentinaMultiple Sclerosis and Related Disorders, 2023
- Decision making process in multiple sclerosis: An Argentine pilot studyMultiple Sclerosis and Related Disorders, 2022
- A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in ChilePharmacoEconomics - Open, 2021
- Annual Cost Burden by Level of Relapse Severity in Patients with Multiple SclerosisAdvances in Therapy, 2020
- The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directionsMultiple Sclerosis and Related Disorders, 2019
- Health Care Cost for Multiple Sclerosis: The Case of a Health Insurer in ColombiaValue in Health Regional Issues, 2018
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Multiple SclerosisNew England Journal of Medicine, 2018
- Increasing prevalence of multiple sclerosis in Buenos Aires, ArgentinaMultiple Sclerosis and Related Disorders, 2016
- Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosisActa Neurologica Belgica, 2013